Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MatsukiyoCocokara & Co. (3088.T)
JPY2,492.00
-36.00 (-1.42%)
JP JPX Healthcare Medical - Pharmaceuticals
Address
9-1 Shinmatsudo-Higashi 270-8511
Matsudo, JP
Matsudo, JP
CEO
Kiyoo Matsumoto
Website
matsukiyococokara.com
IPO
2001-01-04
ISIN JP3869010003
Also trades on
Other OTC · MSMKF (USD)
Tokyo Stock Exchange · 3088.T (JPY)
Description
MatsukiyoCocokara & Co., a Japanese enterprise, manages an extensive chain of pharmacies and drugstores throughout the nation. By June 30, 2020, its operations included 1,726 establishments distributed across all 47 prefectures of Japan. The company was founded in 1932 and maintains its headquarters in Matsudo, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY2,492.00
-36.00 (-1.42%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
-0.20
Float Shares
312.80M
Free Float %
78.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.90% | -5.93% | -8.57% | -18.88% | -23.26% | -17.83% | -23.28% | -8.61% | +61.79% | +138.93% | +494.67% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2,492.00
DCF (Unlevered)
9,740.67
+290.9%
DCF (Levered)
10,912.64
+337.9%
Ratings Trend (MoM)
70% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 5 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.39
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +9.5%+3.8% Q1'26: +6.9% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +18.1%+6.8% Q1'26: -0.7% (vs Q1'25)
-
FCF margin Medical - Pharmaceuticals: +29.9%+5.7% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +4.8%+7.8% ★ Q1'26: +7.7% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.0%+13.1% ★ Q1'26: +12.7% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: -0.1%-2.2% ★ Q1'26: -1.3% (vs Q1'25)
-
Debt / EBITDA Medical - Pharmaceuticals: -0.11×0.02× ★ Q1'26: 0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 10 Rev. Ana. 10 EPS Ana. |
Mar 2027 5 Rev. Ana. 2 EPS Ana. |
Mar 2028 9 Rev. Ana. 9 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
485.51B
est: 489.22B (-0.8%)
|
536.05B
est: 533.44B (+0.5%)
|
535.13B
est: 543.18B (-1.5%)
|
558.88B
est: 559.57B (-0.1%)
|
575.99B
est: 578.40B (-0.4%)
|
590.59B
est: 592.05B (-0.2%)
|
544.74B
est: 564.34B (-3.5%)
|
729.97B
est: 735.01B (-0.7%)
|
951.25B
est: 955.79B (-0.5%)
|
1.02T
est: 1.03T (-1.1%)
|
1.06T
est: 1.06T (-0.1%)
|
1.12T
1.11T – 1.13T
+5.0% YoY
|
1.16T
1.16T – 1.17T
+4.4% YoY
|
1.20T
1.19T – 1.23T
+3.3% YoY
|
1.24T
1.24T – 1.24T
+2.7% YoY
|
1.26T
1.25T – 1.28T
+1.7% YoY
|
| EBITDA |
24.79B
est: 44.43B (-44.2%)
|
34.99B
est: 48.45B (-27.8%)
|
36.38B
est: 49.33B (-26.3%)
|
41.27B
est: 50.82B (-18.8%)
|
44.26B
est: 52.53B (-15.7%)
|
45.96B
est: 53.77B (-14.5%)
|
40.40B
est: 51.25B (-21.2%)
|
56.39B
est: 66.75B (-15.5%)
|
83.54B
est: 86.80B (-3.8%)
|
98.60B
est: 137.19B (-28.1%)
|
105.29B
est: 140.97B (-25.3%)
|
148.05B
146.74B – 149.75B
+5.0% YoY
|
154.55B
153.91B – 155.54B
+4.4% YoY
|
159.69B
157.54B – 163.20B
+3.3% YoY
|
164.05B
164.04B – 164.05B
+2.7% YoY
|
166.88B
165.40B – 169.28B
+1.7% YoY
|
| EBIT |
17.63B
est: 34.56B (-49.0%)
|
27.42B
est: 37.69B (-27.3%)
|
28.43B
est: 38.38B (-25.9%)
|
33.57B
est: 39.53B (-15.1%)
|
36.03B
est: 40.87B (-11.8%)
|
37.55B
est: 41.83B (-10.2%)
|
31.82B
est: 39.87B (-20.2%)
|
41.53B
est: 51.93B (-20.0%)
|
62.70B
est: 67.53B (-7.1%)
|
76.24B
est: 109.05B (-30.1%)
|
82.69B
est: 112.05B (-26.2%)
|
117.68B
116.64B – 119.03B
+5.0% YoY
|
122.85B
122.34B – 123.64B
+4.4% YoY
|
126.94B
125.23B – 129.73B
+3.3% YoY
|
130.40B
130.39B – 130.40B
+2.7% YoY
|
132.65B
131.47B – 134.55B
+1.7% YoY
|
| Net Income |
11.62B
est: 13.80B (-15.8%)
|
17.85B
est: 22.90B (-22.0%)
|
20.12B
est: 24.34B (-17.3%)
|
22.76B
est: 29.54B (-23.0%)
|
25.04B
est: 32.83B (-23.7%)
|
26.18B
est: 33.66B (-22.2%)
|
21.60B
est: 31.85B (-32.2%)
|
34.38B
est: 37.93B (-9.4%)
|
40.55B
est: 40.05B (+1.2%)
|
52.35B
est: 51.11B (+2.4%)
|
54.68B
est: 53.47B (+2.2%)
|
57.14B
56.12B – 61.26B
+6.9% YoY
|
61.85B
61.59B – 62.10B
+8.2% YoY
|
64.11B
59.97B – 71.95B
+3.7% YoY
|
68.54B
63.95B – 75.59B
+6.9% YoY
|
79.56B
78.64B – 81.04B
+16.1% YoY
|
| SGA |
115.38B
est: 99.65B (+15.8%)
|
120.69B
est: 108.66B (+11.1%)
|
121.49B
est: 110.64B (+9.8%)
|
127.94B
est: 113.98B (+12.2%)
|
135.05B
est: 117.82B (+14.6%)
|
143.48B
est: 120.60B (+19.0%)
|
131.08B
est: 114.95B (+14.0%)
|
184.02B
est: 149.71B (+22.9%)
|
246.24B
est: 194.68B (+26.5%)
|
256.14B
est: 259.34B (-1.2%)
|
267.47B
est: 266.49B (+0.4%)
|
279.88B
277.39B – 283.08B
+5.0% YoY
|
292.16B
290.95B – 294.04B
+4.4% YoY
|
301.89B
297.82B – 308.52B
+3.3% YoY
|
310.11B
310.11B – 310.11B
+2.7% YoY
|
315.48B
312.67B – 320.00B
+1.7% YoY
|
| EPS |
35.94
est: 33.76 (+6.4%)
|
55.48
est: 56.03 (-1.0%)
|
63.02
est: 59.56 (+5.8%)
|
71.68
est: 72.30 (-0.9%)
|
79.81
est: 80.34 (-0.7%)
|
85.01
est: 82.39 (+3.2%)
|
70.15
est: 77.95 (-10.0%)
|
93.81
est: 92.84 (+1.1%)
|
96.02
est: 97.95 (-2.0%)
|
125.31
est: 124.63 (+0.5%)
|
133.85
est: 130.41 (+2.6%)
|
142.38
137.33 – 149.93
+9.2% YoY
|
151.36
150.74 – 151.98
+6.3% YoY
|
161.30
146.77 – 176.09
+6.6% YoY
|
170.75
156.51 – 185.00
+5.9% YoY
|
194.70
192.45 – 198.33
+14.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-14 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-13 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-10 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
5.24B
OE per share TTM
12.77
Owner's Yield
0.57%
Maintenance CapEx ratio
7.10%
Maint CapEx / Avg PPE
12.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
6.40M
Shares Outstanding
397.93M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kiyoo Matsumoto | Chief Executive Officer, President & Representative Director | 206M | male |
| Atsushi Tsukamoto | Executive VP & Representative Director | — | male |
| Hiraku Aoki | Executive Officer | — | — |
| Hiroshi Nishida | Executive Officer, Group Management Head & Financial Strategy Office | — | male |
| Shingo Obe | Senior MD & Head of Group Management | — | male |
| Takashi Matsuda | Deputy Head of Group Sales Planning & Director | — | male |
| Takashi Matsumoto | EVP, Head of Group Sales Planning & Representative Director | — | male |
| Taro Yamauchi | Executive Officer | — | — |
| Akio Ishibashi | MD, Head of Group Management Planning & Director | — | male |
| Tsuyoshi Yamamoto | Head of Group Business Planning & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3088.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
